Month: June 2021

Therapeutic Companies will get 3.2 Billion in R and D Support

Posted on by Admin


Companies Developing Therapeutics to Fight Covid-19 Will get a $3.2 Billion Injection

 

Some antiviral pills related to coronavirus will get a $3.2 billion shot in the arm to help accelerate testing and development of therapeutics to combat the Covid-19 virus. This was announced (6/17/21) by the Department of Health and Human Services.

“New antivirals that prevent serious Covid-19 illness and death, especially oral drugs that could be taken at home early in the course of disease, would be powerful tools for battling the pandemic and saving lives,” said President Biden’s, chief medical adviser, Dr. Anthony Fauci.  

The $3.2 billion allocated will be from the $1.9 trillion coronavirus relief package Biden signed into law in March.  Dr. Fauci said the funding could accelerate clinical trials “already in progress” for some antiviral pills and potentially make candidates available by year’s end. He noted that antiviral pills that patients can use to self-treat at home would serve as an important compliment to vaccinations in preventing severe illness or hospitalization.

There are a number of small and microcap biopharmaceutical companies that are in various stages of exploring new antiviral treatments for Covid and other threats. With Washington’s $3.2 billion as yet unallocated support, perhaps some of these are worth visiting.

CoCrystal Pharma, Inc. (Nasdaq:COCP) is a clinical-stage biotechnology company employing its unique structure-based technologies and Nobel Prize-winning expertise to create and develop first- and best-in-class broad-spectrum antiviral drugs for serious and/or chronic diseases. These technologies are designed to efficiently deliver small-molecule therapeutics that target the viral replication process and are safe, effective and convenient to administer. Cocrystal’s development programs include influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

52 Week Range $0.76-$3.46

CytoDyn, Inc. (OTC:QB CYDY) Inc. is US-based clinical-stage biotechnology company which focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. IPIX will hold a webcast on June 21 to Discuss Unblinded Data from COVID-19 Long-Haulers Trial and Other Developments .

52 week price range $1.63-$10.01

Avalon GloboCare Corp. (Nasdaq:AVCO) Avalon GloboCare, a leading biotechnology company focusing on cell-based technology and therapeutics, is about to launch clinical trials of its novel blood filtration system to mitigate symptoms of a cytokine storm in COVID-19 patients and a mucosal intranasal spray vaccination against SARS-CoV-2.

52 week price range $0.87- $2.16

 

Too Many to List

Other companies at various stages of testing development can be found below the article by scrolling down. Click on the tickers for more details on their work and data on the company.

 

Suggested Reading:

Capitalism Vs Coronavirus (April 2020)

Stem Cell Based Therapies for Alzheimer’s Disease



Avalon GloboCare at the World Stem Cell Summit

HealthyLynked at the World Stem Cell Summit

 

Sources:

https://www.hhs.gov/about/news/2021/06/17/biden-administration-invest-3-billion-american-rescue-plan-as-part-covid-19-antiviral-development-strategy.html

https://www.nature.com/articles/d43747-020-01139-4

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Onconova Therapeutics Announces The Peer-Reviewed Publication Of Preclinical Data Demonstrating The Synergistic Anti-Cancer Activity Of Rigosertib

Posted on by Admin


Onconova Therapeutics Announces The Peer-Reviewed Publication Of Preclinical Data Demonstrating The Synergistic Anti-Cancer Activity Of Rigosertib Combined With Immune Checkpoint Blockade

 

igosertib synergistically combined with immune checkpoint blockade (ICB) to improve tumor growth inhibition and survival in a murine melanoma model that did not respond to ICB alone

Rigosertib’s anti-cancer activity was due to its ability to reverse immunosuppressive tumor microenvironments

Data support the clinical evaluation of rigosertib in combination with immune checkpoint inhibitors

NEWTOWN, Pa., June 17, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of a preclinical study in the journal Molecular Cancer. The study, entitled “Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade,” showed that rigosertib synergistically enhanced the efficacy of ICB in a murine melanoma model via the induction of immune-mediated cancer cell death.

“The data from this recent publication demonstrate rigosertib’s potential to address a pressing unmet need, as many patients do not respond to immune checkpoint blockade due to immunosuppressive tumor microenvironments,” said Ann Richmond, Ph.D., Ingram Professor of Pharmacology and Medicine at the Vanderbilt University School of Medicine and lead author of the study. “By reversing immunosuppressive tumor microenvironments, rigosertib overcame pro-tumor resistance mechanisms and synergistically enhanced the efficacy of immune checkpoint blockade in a difficult-to-treat murine melanoma model. These compelling findings provide preclinical proof-of-concept for rigosertib-immune checkpoint blockade combination therapy and strongly support its evaluation in clinical trials.”   

Key data and conclusions from the recent publication include:

  • Rigosertib treatment enhanced the activation of anti-cancer immune cells and increased the frequency of these cells in the tumor microenvironment (TME).
  • Rigosertib treatment reduced the frequency of pro-tumor CD206+ M2-like macrophages in the TME.
  • Rigosertib monotherapy rapidly reduced PI3K signaling with induction of CD40 expression, leading to melanoma cell death and inhibition of tumor growth in vivo due to its ability to promote the tumor infiltration of activated anti-cancer immune cells.
  • Rigosertib’s ability to remodel the TME enabled it to synergistically combine with ICB and improve tumor growth inhibition and survival in a mouse model of melanoma that did not respond to ICB alone, or a clinically used combination of ICB plus BRAF and MEK inhibitors.

Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added, “We are very pleased with these recently published results, which will inform the data driven approach guiding our clinical rigosertib investigator-initiated study program. They provide strong mechanistic support for both the ongoing KRAS mutated non-small cell lung cancer trial of rigosertib in combination with a check point inhibitor and a potential trial in patients with advanced melanoma evaluating a rigosertib-checkpoint inhibitor combination that is under active consideration. Looking ahead, we plan to continue leveraging our collaborations with leading institutions such as Vanderbilt University as we pursue opportunities for rigosertib while maintaining our primary focus and resources on our lead ON 123300 multi-kinase inhibitor program.”

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ non-small cell lung cancer with oral rigosertib in combination with nivolumab. In addition, Onconova continues to conduct preclinical work investigating rigosertib in COVID-19.

For more information, please visit www.onconova.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the timing of Onconova’s and investigator-initiated clinical development plans, and the mechanisms and indications for Onconova’s product candidates. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova’s clinical trials and regulatory agency and institutional review board approvals of protocols, the timing of the Company’s annual stockholder meeting, market conditions and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:

Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:

Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

Release – Palladium One Intercepts More High-Grade Nickel at Tyko Nickel-Copper Project in Ontario Canada

Posted on by Admin


Palladium One Intercepts More High-Grade Nickel Including, 6.0% Nickel_Eq (13.9% Cu_Eq) Over 5.0 Meters at Tyko Nickel-Copper Project, in Ontario, Canada

 

  • Second conductor confirmed to host high-grade massive to semi massive sulphide mineralization.
  • Nickel-copper continuity confirmed along 350-meter, near surface, strike length.
  • 9.5% Ni_Eq over 1.7 meters, within 6.0% Ni_Eq over 5.0 meters, from 66 meters down hole (TK21-034).
  • 9.0% Ni_Eq over 0.9 meters, within 7.8% Ni_Eq over 3.1 meters, from 31 meters down hole (TK21-029).
  • 7.7% Ni_Eq over 1.1 meters, within 7.0% Ni_Eq over 3.5 meters, from 45 meters down hole (TK21-030).

Toronto, Ontario–(Newsfile Corp. – June 17, 2021) – Initial results have been received from the Phase II Tyko drill program said Palladium One Mining (TSXV: PDM) (FRA: 7N11) (OTCQB: NKORF) (“Palladium One” or the “Company”) today. The Phase II program was designed to test the down dip continuity of the EM Maxwell Plate “Plates” that were modelled subsequent to the Q4 2020 Phase I drill program.

A total of 14 holes were completed, 11 of which intersected massive and/or semi-massive sulphide mineralization at the Smoke Lake Zone, which previously returned up to 9.9% Nickel equivalent (23% Copper equivalent, 30.1 g/t Gold equivalent*) (8.1% Ni, 2.9% Cu, 0.61g/t Pd, 0.71g/t Pt, and 0.02g/t Au) over 3.8 metres (see press release January 19, 2021). This release contains the results for the first 6 holes of the Phase II program.

President and CEO, Derrick Weyrauch commented, “Smoke Lake continues to deliver exceptional nickel grades. These results, notably hole TK21-034 indicate that the upper and lower plates are in fact one continuous sulphide lens. Additionally, evidence exists that the high-grade mineralization has been remobilized, thus seeking the source of mineralization is our top priority.”

The most important result of Phase II drill program was the strike length extension to 350-meters combined with linking high-grade massive sulphide mineralization between the ‘upper conductor’ with the ‘lower conductor’ (see hole TK21-034 which returned 6.0% Ni_Eq (13.9% Copper equivalent, 18.6 g/t Gold equivalent*) over 5.0 meters (Figure 1 and 2)).

The Phase II drill program indicates a continuous elongate lens of high-grade sulphide mineralization that dips to the west and plunges to the northwest. Significantly, the sulphide mineralization appears to be remobilized and injected into the tonalite host rocks, cross cutting the foliation in the tonalite and containing well-rounded tonalite and biotite altered hornblendite clasts.

A total of 14 holes totaling 1,370 meters were completed before a significant drill breakdown combined with the onset of early spring conditions forced the suspension of the drill program. Drilling is planned to resume once Geotech’s VTEMmax airborne EM survey and the summer field program have been concluded.

Table 1: Tyko 2021 Phase II Drill Results from the Smoke Lake Zone

Hole From (m) To (m) Width (m) Ni_Eq % Cu_Eq % Au_Eq g/t* Ni % Cu % Co % PGE g/t (Pd+Pt+Au) Pd g/t Pt g/t Au g/t
TK21-029 30.4 37.0 6.6 3.97 9.25 12.29 3.08 1.59 0.04 0.56 0.30 0.25 0.01
Inc. 31.1 34.1 3.1 7.80 18.21 24.07 6.22 2.77 0.08 1.10 0.61 0.48 0.02
Inc. 31.1 33.3 2.2 8.65 20.19 26.52 7.13 2.51 0.09 1.29 0.72 0.55 0.02
Inc. 31.1 32.0 0.9 9.05 21.12 27.38 7.90 1.52 0.11 1.30 0.75 0.53 0.02
TK21-030 45.0 59.2 14.1 2.21 5.15 6.79 1.76 0.71 0.03 0.38 0.16 0.22 0.01
Inc. 45.0 48.5 3.5 6.97 16.27 21.35 5.68 2.19 0.08 0.89 0.45 0.42 0.02
Inc. 46.4 47.6 1.1 7.72 18.02 23.14 6.93 0.97 0.09 0.91 0.52 0.37 0.02
And 58.2 59.2 1.0 4.43 10.33 13.73 3.38 0.93 0.12 1.95 0.58 1.35 0.02
Inc. 58.2 58.8 0.6 5.88 13.72 18.21 4.49 1.12 0.17 2.75 0.78 1.95 0.03
TK21-031 41.9 44.6 2.7 3.88 9.05 12.15 2.88 1.78 0.04 0.70 0.34 0.33 0.03
Inc. 42.4 44.0 1.6 6.32 14.74 19.75 4.73 2.84 0.07 1.08 0.55 0.51 0.02
Inc. 42.8 44.0 1.2 8.09 18.88 25.23 6.13 3.48 0.09 1.37 0.68 0.66 0.02
TK21-032 63.4 69.8 6.5 1.82 4.24 5.77 1.29 0.91 0.02 0.47 0.22 0.24 0.00
Inc. 63.4 67.6 4.2 2.49 5.81 7.91 1.76 1.25 0.03 0.65 0.31 0.33 0.01
Inc. 65.7 66.1 0.4 4.91 11.45 15.00 4.02 1.10 0.05 1.54 0.47 1.06 0.01
TK21-033 55.4 72.0 16.6 1.20 2.81 3.75 0.92 0.50 0.01 0.21 0.10 0.11 0.00
Inc. 61.5 68.0 6.5 2.55 5.95 7.91 1.97 1.02 0.03 0.42 0.20 0.22 0.00
Inc. 66.3 68.0 1.8 6.58 15.36 19.69 5.91 0.84 0.06 0.94 0.39 0.55 0.01
Inc. 67.7 68.0 0.4 9.32 21.75 27.99 8.32 1.43 0.08 1.04 0.62 0.42 0.01
TK21-034 66.3 73.0 6.7 4.57 10.67 14.30 3.42 2.05 0.05 0.81 0.39 0.40 0.01
Inc. 66.3 71.3 5.0 5.95 13.88 18.57 4.47 2.62 0.06 1.06 0.51 0.53 0.02
Inc. 66.3 68.8 2.5 8.42 19.65 26.18 6.45 3.52 0.08 1.37 0.67 0.68 0.02
Inc. 66.3 68.0 1.7 9.54 22.26 29.46 7.50 3.51 0.09 1.64 0.73 0.88 0.02
Inc. 67.5 68.0 0.5 9.81 22.89 29.92 8.12 2.95 0.09 1.17 0.57 0.58 0.02
Holes TK21-035 to TK21-043 Results Pending

 

(1) Reported widths are “drilled widths” not true widths.
* Gold Equivalent (Au_Equivalent) is calculated for comparison purposes using recent spot prices, $8lb nickel, $4.4/lb copper, $19/lb cobalt, $2,700/oz palladium, $1,150/oz platinum, $1,900/oz gold.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6502/87835_b9f71a38042c4a5d_001.jpg

Figure 1. Smoke Lake plan map showing EM conductor Plates with 2020 and 2021 (blue traces) drill holes overlain on first vertical magnetics. Mineralized intersections for drill holes for which assays are still pending are given in meters, MS = massive sulphide, SM = semi-massive, STR = stringer, DISS = Disseminated.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6502/87835_b9f71a38042c4a5d_002.jpg

Figure 2. Smoke Lake cross section showing continuity of the massive sulphide mineralization from the upper to lower EM plates.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6502/87835_b9f71a38042c4a5d_003.jpg

Figure 3. Massive and semi-massive magmatic sulphide intersections in holes TK-21-029, 30 and 35. Wall rock is tonalite, and hornblendite.

*Nickel Equivalent (“Ni_Eq”) and Copper Equivalent (“Cu_Eq”)

Nickel and copper equivalent is calculated using US$1,100 per ounce for palladium, US$950 per ounce for platinum, US$1,300 per ounce for gold, US$6,614 per tonne (US$3.00 per pound) for copper, US$15,432 per tonne (US$7.00 per pound) for nickel and US$30,865 per tonne (US$14 per pound) for Cobalt. This calculation is consistent with the commodity prices used in the Company’s September 2019 NI 43-101 Kaukua resource estimate.

QA/QC

The Phase II drilling program was carried out under the supervision of Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company.

Drill core samples were split using a rock saw by Company staff, with half retained in the core box. The drill core samples were transported by company staff the Company’s core handling facility, to Actlabs laboratory in Thunder Bay, Ontario. Actlabs, is an accredited lab and are ISO compliant (ISO 9001:2015, ISO/IEC 17025:2017). PGE analysis was performed using a 30 grams fire assay with an ICP-MS or ICP-OES finish. Multi-element analyses, including copper and nickel were analysed by four acid digestion using 0.5 grams with an ICP-MS or ICP-OES finish.

Certified standards, blanks and crushed duplicates are placed in the sample stream at a rate of one QA/QC sample per 10 core samples. Results are analyzed for acceptance at the time of import. All standards associated with the results in this press release were determined to be acceptable within the defined limits of the standard used.

About Tyko Ni-Cu-PGE Project

The Tyko Ni-Cu-PGE Project, is located approximately 65 kilometers northeast of Marathon Ontario, Canada. Tyko is an early stage, high sulphide tenor, nickel-copper (2:1 ratio) project with the most recent drill hole intercepts returning up to 9.9% Ni_Eq over 3.8 meters (8.1% Ni, 2.9% Cu, 1.3g/t PGE) in hole TK-20-023.

Qualified Person

The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43-101.

About Palladium One

Palladium One Mining Inc. is an exploration company targeting district scale, platinum-group-element (PGE)-copper-nickel deposits in Finland and Canada. Its flagship project is the Läntinen Koillismaa or LK Project, a palladium-dominant platinum group element-copper-nickel project in north-central Finland, ranked by the Fraser Institute as one of the world’s top countries for mineral exploration and development. Exploration at LK is focused on targeting disseminated sulfides along 38 kilometers of favorable basal contact and building on an established NI 43-101 open pit resource.

ON BEHALF OF THE BOARD
“Derrick Weyrauch”
President & CEO, Director

For further information contact:
Derrick Weyrauch, President & CEO
Email: info@palladiumoneinc.com

Neither the TSX Venture Exchange nor its Market Regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release is not an offer or a solicitation of an offer of securities for sale in the United States of America. The common shares of Palladium One Mining Inc. have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

Information set forth in this press release may contain forward-looking statements. Forward-looking statements are statements that relate to future, not past events. In this context, forward-looking statements often address a company’s expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in palladium and other commodity prices; title matters; environmental liability claims and insurance; reliance on key personnel; the absence of dividends; competition; dilution; the volatility of our common share price and volume; and tax consequences to Canadian and U.S. Shareholders. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

Release – Comtech Telecommunications Corp. Awarded 5 Million Contract to Deploy a Next Generation 911 Solution

Posted on by Admin


Comtech Telecommunications Corp. Awarded $5.0 Million Contract to Deploy a Next Generation 911 Solution to a U.S. Government End Customer

 

MELVILLE, N.Y.–(BUSINESS WIRE)–Jun. 17, 2021– 
June 17, 2021— 
Comtech Telecommunications Corp. (NASDAQ: CMTL), a world leader in secure wireless communications technologies, announced today, that 
Comtech Solacom Technologies, Inc., a division of Comtech’s Commercial Solutions segment, was awarded a Next Generation 911 (“NG 911”) modernization project for a 
U.S. Government end customer. Of the total 
$5.0 million contract value, 
$3.2 million was awarded to 
Comtech in its fourth fiscal quarter.

Comtech Solacom will provide a full turnkey solution, including all hardware and software, installation, and training for a multi-node, geographically dispersed Guardian call management system. The Guardian solution will be deployed in a redundant, multi-geo-diverse configuration ensuring the highest possible service availability with an intuitive user interface allowing call takers to quickly assess, prioritize and handle landline, wireless and VoIP emergency calls. Call takers can quickly create conferences, transfer calls, determine the location of callers and replay recently recorded conversations.

“Comtech’s commitment to innovative next generation emergency communication solutions has been recognized by the selection of the Solacom Guardian solution to modernize the 911 operations of a major 
U.S. Government end customer. Deployed and supported in close cooperation with the prime contractor, the Guardian solution will further enhance our long-standing partnership with this customer allowing them to focus on critical missions,” said  Fred Kornberg, Chairman of the Board and Chief Executive Officer of 
Comtech Telecommunications Corp.

Comtech Solacom emergency call handling and management solutions are built on more than 30 years of research and innovation in the application of advanced hardware and software technologies for public safety. For more information, visit: www.solacom.com.

Comtech Telecommunications Corp. is a leader in the global communications market headquartered in 
Melville, New York. With a passion for customer success, 
Comtech designs, produces and markets advanced secure wireless solutions to more than 1,000 customers in more than 100 countries. For more information, please visit www.comtechtel.com.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s 
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such 
Securities and Exchange Commission filings.

Media Contact:
Michael D. Porcelain, President and Chief Operating Officer

Comtech Telecommunications Corp.
631-962-7000
info@comtechtel.com

Source: 
Comtech Telecommunications Corp.

Ocugen Inc. Set to Join Russell 3000® Index

Posted on by Admin


Ocugen Inc. Set to Join Russell 3000® Index

 

MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

The annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, 2021, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“As part of the reconstitution process to ensure that new and growing equities are included, we are pleased to be added to the Russell 3000® index which measures the performance of the largest US companies representing approximately 98% of the investable US equity market,” said Sanjay Subramanian, CFO and Head of Corporate Development of Ocugen.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the US and Canadian markets. For more information, please visit http://ocugen.com/

About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit https://www.ftserussell.com/.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corp. Dev.
IR@Ocugen.com

Media Contact:
LaVoieHealthScience
Lisa DeScenza
ldescenza@lavoiehealthscience.com
+1 978-395-5970

QuickChek – June 16, 2021

Posted on by Admin



Sierra Metals Announces Receipt Of Permit Allowing For A 20% Increase Of Throughput To 3,600 Tonnes Per Day At Its Yauricocha Mine In Peru

Sierra Metals announced the receipt of an Informe Técnico Minero (“ITM”) Permit from the Peruvian Ministry of Energy and Mines

Research, News & Market Data on Sierra Metals

Watch recent presentation from Sierra Metals



Ocugen Inc. Set to Join Russell 3000® Index

Ocugen Inc. announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution

Research, News & Market Data on Ocugen

Watch recent presentation from NobleCon17



electroCore to Join Russell Microcap® Index

electroCore announced the addition of its stock to the broad-market Russell Microcap® Index after its 2021 annual reconstitution

Research, News & Market Data on electroCore



Kratos Named One of the First Cybersecurity Maturity Model Certification (CMMC) Third Party Assessment Organizations (C3PAO)

Kratos Defense & Security Solutions announced that it has been named by the federal government as one of the first two Third Party Assessment Organizations (C3PAO)

Research, News & Market Data on Kratos



Lineage Cell Therapeutics Announces Kevin L. Cook To Join As Chief Financial Officer

Lineage Cell Therapeutics announced that Kevin Cook will join as the Company’s Chief Financial Officer, effective June 21, 2021

Research, News & Market Data on Lineage Cell Therapeutics

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

electroCore to Join Russell Microcap® Index

Posted on by Admin


electroCore to Join Russell Microcap® Index

 

ROCKAWAY, NJ, 
June 16, 2021 (GLOBE NEWSWIRE) —  
electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today the addition of its stock to the broad-market Russell Microcap® Index after its 2021 annual reconstitution, effective after the open of trading on 
June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on 
June 4, 2021.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“We are pleased to have been selected to join the Russell Microcap® Index,” said  Brian Posner, Chief Financial Officer of electroCore. “Inclusion in the index should increase our exposure to the investment community and represents an important step in providing continued value for our shareholders.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately 
$10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the impact of electroCore’s inclusion in the Russell Microcap® Index, electroCore’s business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular to treat COVID-19, and other statements that are not historical in nature, particularly those using terminology such as “anticipates,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore’s business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the 
SEC, available at www.sec.gov.


Investors:
Rich CockrellCG Capital
404-736-3838
ecor@cg.capital

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
summer.diaz@electrocore.com

Kratos Named One of the First Cybersecurity Maturity Model Certification (CMMC) Third Party Assessment Organizations (C3PAO)

Posted on by Admin


Kratos Named One of the First Cybersecurity Maturity Model Certification (CMMC) Third Party Assessment Organizations (C3PAO)

 

SAN DIEGO, 
June 15, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has been named by the federal government as one of the first two CMMC Third Party Assessment Organizations (C3PAO). As a C3PAO, Kratos will be able to conduct CMMC Level 1-3 assessments once the government completes certain preparatory and authorization steps.

The CMMC is a new unified security standard and a certification process developed by the 
U.S. Department of Defense (
DoD) to protect the security of Federal Contract Information (FCI) and Controlled Unclassified Information (CUI) within the Defense Industrial Base (DIB). In accordance with recent updates to DFARS 252.204, the 
Office of the Under Secretary of Defense (OUSD) will begin a phased rollout requiring contractors to achieve CMMC certification. Once the rollout is complete, nearly all companies seeking to respond to 
DoD proposal requests will require CMMC certification.

Kratos has years of robust experience in compliance and certification, risk management and cyber operations, defense and engineering. Services include vulnerability assessments, enterprise security architecture design, application security testing and risk management processes. Kratos cybersecurity services support the development and operation of proactive cybersecurity programs, the development of enterprise cloud security strategies, and the establishment of sound and practical information security architectures tailored to organizational needs.

Mark Williams, Vice President, Kratos Cybersecurity Services explained: “As a member of the DIB Kratos underwent a rigorous assessment by the Defense Industrial Base Cybersecurity Assessment Center, which was a key factor in its early C3PAO authorization by the 
CMMC AB.” Once authorized to begin conducting assessments. Kratos’ Provisional Assessor-led teams will conduct the CMMC assessments that consist of up to four phases. The Planning phase includes assessment plan development and an assessment readiness review. The Assessment phase includes collecting and validating the required Objective Evidence (OE) and generating final results. Presentation of the results occurs in the Report Findings phase. If issues are identified in the Report Findings phase, the Remediation phase is dedicated to evaluating remedial actions taken. Depending on the assessment complexity Kratos estimates that most assessments will be completed in four to six weeks.

Phil Carrai, President of Kratos Space, Training and Cyber Division highlighted the importance of a robust CMMC program. “The recent spate of data breaches affecting both government and commercial organizations underscores the need for more robust security measures to protect critical information. For 
DoD this means increased protection of FCI and CUI data. CMMC will be a critical component of heightened security as all companies will need to pass strict CMMC security assessments before being awarded 
DoD contracts. Kratos is proud to be named one of the first C3PAOs. Our extensive experience in providing advisory and assessment services for compliance frameworks such as FedRAMP and others position us well to support CMMC.”

For more information on Kratos’ CMMC services visit: https://www.kratosdefense.com/cmmc-c3pao.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. Kratos specializes in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
investor@kratosdefense.com

Source: Kratos Defense & Security Solutions, Inc.

China Fighting Cost Push Inflation with Metals Reserves

Posted on by Admin


Why are the Chinese Releasing Copper, Aluminum, and Zinc Reserves?

 

When the U.S. Federal Reserve looks to curb producer price inflation, they may take money out of the economy to impact the demand side of the equation. When China is looking to squelch its factory gate inflation, they grow the supply side by releasing reserves of raw materials. At least that is what they announced today (6/16) related to some base metals. 

China is the world’s top metals consumer. A spike in inflation of Chinese made goods would reduce the countries global competitive position. This could lead to decreased exports. For this reason, it’s in the countries best interest to cool the roaring price increases of copper, aluminum, zinc, and others. Prices have been surging this year in reaction to post-pandemic spikes in demand and some speculative buying around the commodities. With today’s announcement, speculators are warned that buying may lead to unintended “pain.” This alone helps to tame prices at the producer or factory stage. 

 

Background/ What is Impacted

Chinese factory gate inflation is the rough equivalent to the U.S. Bureau of Labor Statistics measure of producer price inflation. Factory gate prices jumped to the highest level in over 12 years during May. The higher costs cut into profit margins of final product producers because much of the cost was not able to be passed on to consumers. Global price pressures have been on the rise in many countries as policymakers have been working to revitalize post-Covid-19 economies without unwanted inflation. The balance needed to achieve both has been a growing challenge.

Prices on copper contracts on the Shanghai Futures Exchange and the London Metal Exchange hit record highs in May, after having risen more than 60% since March 2020 as the reaction to the pandemic began to affect global markets. On their website, the Chinese National Food and Strategic Reserves Administration said that it will release reserves for public bid including copper, aluminum, and zinc in batches for nonferrous processing and manufacturing. The sales are not completely unexpected by metals traders as Chinese regulators have been stepping up efforts to cool commodity prices in recent weeks.

 

Take-Away

The Chinese authorities are trying to help support the margins of its manufacturing industry as passing along manufacturing costs to end consumers have not been overly successful. This bodes well for the argument that recent spikes in inflation may be temporary and related to spikes in demand that will level out over time. The Chinese National Food and Strategic Reserves Administration is doing its part to add supplies at a time when demand and speculation of increased demand is at an abnormal peak. The move may help to calm the volatility we have seen in other parts of the world in commodity prices.

Today the Federal Open Market Committee (FOMC) will end their two-day June meeting where U.S. inflation is on their agenda as well. The world markets await being updated on the Fed’s plans for scaling back what are seen as inflationary monetary policies. The Fed statement post meeting typically is made public at 2 pm following the FOMC’s adjournment.

 

Suggested Reading:

The PCE Deflator and the Trimmed PCE Inflation Rate Tell Different Stories

Will Mortgage Forbearance Impact Other Markets?



How Much is a Trillion?

Bond Market Understanding is Now Critical for Stock Investors

 

Virtual Road Show Series – Thursday, Jun 17, @ 1pm EDT

Join Chakana Copper CEO David Kelley for this exclusive corporate presentation, followed by a Q & A session moderated by Mark Reichman, Noble’s senior research analyst, featuring questions taken from the audience. Registration is free and open to all investors, at any level.

Register Now  |  View All Upcoming Road Shows

 

Sources:

https://www.wsj.com/articles/china-to-release-metal-reserves-in-effort-to-tame-commodities-rally-11623825424?mod=searchresults_pos3&page=1

https://www.wsj.com/articles/copper-falls-to-eight-week-low-on-fear-china-might-release-stockpiles-11623761899?mod=searchresults_pos5&page=1

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Sierra Metals Announces Receipt Of Permit Allowing For A 20% Increase Of Throughput To 3,600 Tonnes Per Day At Its Yauricocha Mine In Peru

Posted on by Admin


Sierra Metals Announces Receipt Of Permit Allowing For A 20% Increase Of Throughput To 3,600 Tonnes Per Day At Its Yauricocha Mine In Peru

 

TORONTO–(BUSINESS WIRE)– Sierra Metals Inc. (TSX: SMT) (BVL: SMT) (NYSE AMERICAN: SMTS) (“Sierra Metals” or the “Company”) is pleased to announce the receipt of an Informe Técnico Minero (“ITM”) Permit from the Peruvian Ministry of Energy and Mines. The ITM Permit allows for the construction and operation at a capacity of 3,600 tonnes per day (“TPD”), at the Yauricocha Mine in Peru.

Luis Marchese, CEO of Sierra Metals commented: “I am delighted with the receipt of the ITM permit. The Company may now increase throughput at Yauricocha to 3,600 TPD which represents a 20% increase in throughput. Today’s news will further support the Company in achieving its annual production guidance.

Additionally, we continue focusing on the completion of the Prefeasibility Study at Yauricocha, which examines increasing throughput to 5,500 TPD starting in 2024, as well as on the Prefeasibility Studies for our Mexican operations.”

He concluded: “2021 continues to be an exciting year for the Company as we continue with organic growth plans including significant brownfield and greenfield exploration programs to support future mineral resource and production growth. Management also continues to focus on improving and modernizing our mine operations, increasing operating efficiencies to improve productivity and reduce costs.”

About Sierra Metals

Sierra Metals is a diversified Canadian mining company focused on the production and development of precious and base metals from its polymetallic Yauricocha Mine in Peru, and Bolivar and Cusi Mines in Mexico. The Company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new key discoveries and still has many more exciting brownfield exploration opportunities at all three Mines in Peru and Mexico that are within close proximity to the existing mines. Additionally, the Company also has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential.

The Company’s common shares trade on the Toronto Stock Exchange and the Bolsa de Valores de Lima under the symbol “SMT” and on the NYSE American Exchange under the symbol “SMTS”.

Continue to Follow, Like and Watch our progress:

Web: www.sierrametals.com | Twitter: sierrametals | Facebook: SierraMetalsInc | LinkedIn: Sierra Metals Inc | Instagram: sierrametals

Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of Canadian and U.S. securities laws related to the Company (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, statements with respect to the Company’s operations, including anticipated developments in the Company’s operations in future periods, the Company’s planned exploration activities, the adequacy of the Company’s financial resources, and other events or conditions that may occur in the future. Statements concerning mineral reserve and resource estimates may also be considered to constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if and when the properties are developed or further developed. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “assumes”, “intends”, “strategy”, “goals”, “objectives”, “potential” or variations thereof, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking information.

Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in our Annual Information Form dated March 30, 2021 in respect of the year ended December 31, 2020 and other risks identified in the Company’s filings with Canadian securities regulators and the U.S. Securities and Exchange Commission, which filings are available at www.sedar.com and www.sec.gov, respectively.

The risk factors referred to above is not exhaustive of the factors that may affect any of the Company’s forward-looking information. Forward looking information includes statements about the future and are inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations and opinions of management on the date the statements are made, and the Company does not assume any obligation to update forward-looking information if circumstances or management’s beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

For further information regarding Sierra Metals, please visit www.sierrametals.com or contact:

Mike McAllister
V.P., Investor Relations
Sierra Metals Inc.
+1 (416) 366-7777
Email: info@sierrametals.com

Luis Marchese
CEO
Sierra Metals Inc.
+1(416) 366-7777

Source: Sierra Metals Inc.

Release – electroCore to Join Russell Microcap Index

Posted on by Admin


electroCore to Join Russell Microcap® Index

 

ROCKAWAY, NJ, 
June 16, 2021 (GLOBE NEWSWIRE) —  
electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today the addition of its stock to the broad-market Russell Microcap® Index after its 2021 annual reconstitution, effective after the open of trading on 
June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on 
June 4, 2021.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“We are pleased to have been selected to join the Russell Microcap® Index,” said  Brian Posner, Chief Financial Officer of electroCore. “Inclusion in the index should increase our exposure to the investment community and represents an important step in providing continued value for our shareholders.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately 
$10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the impact of electroCore’s inclusion in the Russell Microcap® Index, electroCore’s business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular to treat COVID-19, and other statements that are not historical in nature, particularly those using terminology such as “anticipates,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore’s business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the 
SEC, available at www.sec.gov.


Investors:
Rich CockrellCG Capital
404-736-3838
ecor@cg.capital

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
summer.diaz@electrocore.com

Release – Ocugen Inc. Set to Join Russell 3000 Index

Posted on by Admin


Ocugen Inc. Set to Join Russell 3000® Index

 

MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

The annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, 2021, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

“As part of the reconstitution process to ensure that new and growing equities are included, we are pleased to be added to the Russell 3000® index which measures the performance of the largest US companies representing approximately 98% of the investable US equity market,” said Sanjay Subramanian, CFO and Head of Corporate Development of Ocugen.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the US and Canadian markets. For more information, please visit http://ocugen.com/

About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit https://www.ftserussell.com/.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corp. Dev.
IR@Ocugen.com

Media Contact:
LaVoieHealthScience
Lisa DeScenza
ldescenza@lavoiehealthscience.com
+1 978-395-5970

Aurania Resources (AUIAF)(ARU:CA) – Making the Connection Between Tsenken N1 and Tiria-Shimpia

Posted on by Admin

Wednesday, June 16, 2021

Aurania Resources (AUIAF)(ARU:CA)
Making the Connection Between Tsenken N1 and Tiria-Shimpia

As of April 24, 2020, Noble Capital Markets research on Aurania Resources is published under ticker symbols (AUIAF and ARU:CA). The price target is in USD and based on ticker symbol AUIAF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Aurania Resources Ltd. is a Canada-based junior mining exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities-Cutucu Project, is in southeastern Ecuador in the Province of Morona-Santiago. The company also has several minor projects in Switzerland.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Drilling intersects sediment-hosted copper at Tsenken N1. Drilling intersected sediment-hosted copper mineralization at the Tsenken N1 copper-silver target in the company’s Lost Cities project. Drilling will continue at the Tsenken N1 target with the second rig moving from the Kuri-Yawi epithermal gold-porphyry copper target to to the Tiria-Shimpia silver-zinc target area by the end of June. Management believes that Tsenken and Tiria-Shimpia may be part of the same mineralized system, extending over 45 kilometers, that gradually changes from copper-dominant to zinc-dominant mineralization.

    Two holes drilled at Kuri-Yawi.  Two holes (YW-008 and YW-009) were drilled at the Kuri-Yawi epithermal gold-porphyry copper target representing 1,948 meters of drilling. Drill data will be used to inform the interpretation of MobileMT and magnetic data to refine the location of an epithermal target which lies to the east of Hole 9. Hole 8 was drilled to a depth of 1,212 meters but did not intersect …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.